ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2015-020]

A Pilot Investigation of dark adaptation following intravitreal injection of anti-VEGF agents

The purpose of this pilot study is to determine if treatment with medications targeting vascular endothelial growth factor (VEGF) (e.g. bevacizumab, ranibizumab, and aflibercept) improves the ability of patients with age-related macular degeneration, diabetic macular edema, or a central retinal vein occlusion with macular edema to adjust from light to dark conditions (i.e. dark adaptation).

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3956